Andre Goy, M.D., Chairman and Director of John Theurer Cancer Center, Chief of the Lymphoma Program and Chief Science Officer and Director of Research and Innovation for Regional Cancer Care Associates, announced today positive results from a phase II study of patients with indolent non-Hodgkin lymphoma (iNHL) published in the New England Journal of Medicine (NEJM).
Underscoring their commitment to accelerate and contribute to new targeted treatments for blood cancers, Regional Cancer Care Associates (RCCA) researchers/physicians from John Theurer Cancer Center at HackensackUMC, one of the nation’s top 50 best hospitals for cancer, contributed to more than 35 blood cancer studies presented at the 55th Annual American Society of Hematology (ASH) Meeting in New Orleans from December 7-10.
ndre Goy, M.D., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates, presented new data providing further insight into the complexity of the genomic landscape in high-risk diffuse large B-cell lymphoma (DLBCL), the most common subtype of Non-Hodgkin Lymphoma (NHL) among adults.
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) has announced its inaugural class of 15 oncology practices and institutions for its first-ever Quality Training Program. This six-month program will teach oncology providers to conduct focused quality improvement efforts in their practices.
HACKENSACK, N.J., July 3, 2013 /PRNewswire/ — Members of Regional Cancer Care Associates (RCCA), one of the nation’s largest Oncology physician networks, presented Governor Chris Christie with the 2013 Leadership Award during a ceremony on Tuesday, July 2 at the John Theurer Cancer Center at HackensackUMC. The award honored the Governor for his contributions in the prevention and treatment of cancer.
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for REVLIMID® (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
Regional Cancer Care Associates (RCCA), the largest oncology physician network in New Jersey, is proud to announce that 31 RCCA physicians were recognized as the best in their field by leading regional and national top doctor rankings in 2012.
The escalating cost of cancer care delivery, which accounts for $104.1 billion in medical care expenditures1, has become a major concern to patients, caregivers, policymakers, and insurance companies. If left unchecked, this threatens to limit patient access to life-saving treatments.
The escalating cost of cancer care delivery, which accounts for $104.1 billion in medical care expenditures, has become a major concern to patients, caregivers, policymakers, and insurance companies. If left unchecked, this threatens to limit patient access to life-saving treatments.